Matt Cockerill is the founding Director, Europe for Riffyn. Previously, Matt was the Managing Director and a Founder of BioMed Central, which introduced the open-access publishing model - a model that now dominates academic publishing worldwide. After selling BioMed Central to Springer in 2008, he served on the Springer Management Board and grew the business by 500% in five years. Prior to BioMed Central, Matt lead the development of BioMedNet a community website for medical researchers, which was sold to Reed Elsevier. He holds a bachelors with honors in Natural Sciences and a PhD in molecular biology in the lab of Nobel Laureate Tim Hunt at the Imperial Cancer Research Fund.